SCHEMBL14299290

SCHEMBL14299290

C=C1CC/C(=C/C=C2\CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VDR P11473 12/20 0.75
▸ MAPT P10636 3/20 0.71
▸ SMN1; SMN2 Q16637 2/20 0.71
▸ NR1I2 O75469 1/20 0.71
▸ ABCB11 O95342 1/20 0.71
▸ GC P02774 1/20 0.71
▸ PGR P06401 1/20 0.71
▸ ADORA3 P0DMS8 1/20 0.71
▸ RXRA P19793 1/20 0.71
▸ CHRM3 P20309 1/20 0.71
▸ CNR1 P21554 1/20 0.71
▸ SLC6A2 P23975 1/20 0.71
▸ HTR2C P28335 1/20 0.71
▸ MAPK1 P28482 1/20 0.71
▸ AGTR1 P30556 1/20 0.71
▸ SLC6A4 P31645 1/20 0.71
▸ ADRA1A P35348 1/20 0.71
▸ PTGS2 P35354 1/20 0.71
▸ OPRD1 P41143 1/20 0.71
▸ OPRK1 P41145 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14299294 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL9971821 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL14299295 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL9971811 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL14299288 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL9971738 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL19159234 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL9971745 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL22877969 1.00 VDR (0.75) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL12706969 0.96 VDR (0.69) VDRMAPTSMN1; SMN2NR1I2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2721004-B1 3-DESOXY-2-METHYLENE-19-NOR-VITAMIN D ANALOGS AND THEIR USES WISCONSIN ALUMNI RES FOUND (US) 2017-07-26 — — EP disclosed
US-8993547-B2 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-03-31 — — US disclosed
US-8993547-B2 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-03-31 — — US disclosed
US-20120322775-A1 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-12-20 — — US disclosed
US-20120322775-A1 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322775-A1 3-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses VDR, CYP24A1, CYP2R1 VDR 1/4885MAPT 3557/4885SMN1; SMN2 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback